First-in-human trial aims to boost immune attack on lymphoma
NCT ID NCT07444710
Summary
This early-stage study is testing a new drug, glofitamab, added to standard chemotherapy for people with previously untreated mantle cell lymphoma, a type of blood cancer. The main goal is to find the safest dose of this combination and understand its side effects. Researchers will also check if the treatment helps shrink the cancer and keeps it under control.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANN ARBOR STAGE II MANTLE CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.